VBI Vaccines, Inc. (NASDAQ: VBIV) Starts Presentation at the 2017 Marcum Microcap Conference
VBI Vaccines (NASDAQ: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B vaccine that mimics all three viral surface antigens of the hepatitis B virus. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines. For more information, visit the company's website at www.vbivaccines.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides…







